Literature DB >> 10980995

The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach.

J R Pisegna1.   

Abstract

Zollinger-Ellison syndrome (ZES) is caused by a tumor that secretes gastrin and is the most common of the malignant islet cell tumors. ZES leads to hypergastrinemia, which, in turn, causes an overproduction of gastric acid and results in complications of peptic ulcer disease. Of all the islet cell tumors, gastrinoma tumors have undergone the most extensive study, providing a model of tumor management. Increased awareness and improved biochemical and radiologic techniques mean that these disorders are being recognized in more patients. Advances in the management of gastric acid secretion and new localization methods have significantly reduced the morbidity and mortality associated with ZES. The use of intravenous proton pump inhibitors such as pantoprazole will make surgical and perioperative management more favorable for patients. Radiologic and nuclear medicine studies permit the detection of the majority of islet cell tumors and improve the ability for surgical resection. With the recent cloning of the gene for multiple endocrine neoplasia type I (MEN-I) and the recognition of tumor markers associated with the development of islet cell tumors, early detection of these tumors may someday be possible.

Entities:  

Mesh:

Year:  1999        PMID: 10980995     DOI: 10.1007/s11894-999-0012-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  33 in total

Review 1.  Zollinger-Ellison syndrome: pathogenesis, diagnosis, and management.

Authors:  B I Hirschowitz
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

2.  Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Authors:  R Arnold; M E Trautmann; W Creutzfeldt; R Benning; M Benning; C Neuhaus; R Jürgensen; K Stein; H Schäfer; C Bruns; H J Dennler
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

3.  Management of the Zollinger-Ellison syndrome in pregnancy.

Authors:  C A Stewart; B Termanini; V E Sutliff; V D Corleto; H C Weber; F Gibril; R T Jensen
Journal:  Am J Obstet Gynecol       Date:  1997-01       Impact factor: 8.661

4.  Surgery to cure the Zollinger-Ellison syndrome.

Authors:  J A Norton; D L Fraker; H R Alexander; D J Venzon; J L Doppman; J Serrano; S U Goebel; P L Peghini; P K Roy; F Gibril; R T Jensen
Journal:  N Engl J Med       Date:  1999-08-26       Impact factor: 91.245

5.  An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma.

Authors:  J R Pisegna; G G Slimak; J L Doppman; D B Strader; D C Metz; R V Benya; M Orbuch; V A Fishbeyn; D L Fraker; J A Norton
Journal:  Gastroenterology       Date:  1993-10       Impact factor: 22.682

6.  Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.

Authors:  J R Pisegna; J A Norton; G G Slimak; D C Metz; P N Maton; J D Gardner; R T Jensen
Journal:  Gastroenterology       Date:  1992-03       Impact factor: 22.682

Review 7.  Zollinger-Ellison syndrome: diagnosis and management.

Authors:  R Fass; H R Rosen; J H Walsh
Journal:  Hosp Pract (1995)       Date:  1995-11-15

8.  [Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha].

Authors:  R Nold; M Frank; U Kajdan; U Trost; K J Klose; R Arnold
Journal:  Z Gastroenterol       Date:  1994-04       Impact factor: 2.000

9.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

Review 10.  Zollinger-Ellison syndrome. Recognition and management of acid hypersecretion.

Authors:  P N Maton
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

View more
  5 in total

Review 1.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Reflux laryngitis in a patient with Zollinger Ellison syndrome and the role of epidermal growth factor.

Authors:  Benjamin M Weinberg; David S Oh; Gordon V Ohning; Joseph R Pisegna
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

Review 3.  Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.

Authors:  Joseph R Pisegna
Journal:  Crit Care Med       Date:  2002-06       Impact factor: 7.598

4.  Duodenal bulb mucosa with hypertrophic gastric oxyntic heterotopia in patients with zollinger ellison syndrome.

Authors:  Emil Kohan; David Oh; Hank Wang; Salar Hazany; Gordon Ohning; Joseph R Pisegna
Journal:  Diagn Ther Endosc       Date:  2009-07-01

5.  Gastric Hypersecretory States: Investigation and Management.

Authors:  Jennifer Phan; Jihane N Benhammou; Joseph R Pisegna
Journal:  Curr Treat Options Gastroenterol       Date:  2015-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.